金雀异黄素 (Gen) 是一种天然多酚化合物，已成为治疗肺癌的有希望的候选药物。然而，Gen的潜在临床应用由于其溶解性差、生物利用度低和毒副作用而受到限制。为了应对这些挑战，构建了一种以天然细胞来源的细胞膜作为载体材料的仿生递送平台。这种创新方法旨在促进靶向药物递送并解决合成材料的生物相容性问题。首先，采用乙醇注射法制备了负载Gen的脂质体（LPs@Gen）。随后，将血小板膜（PLTM）与LPs@Gen混合后，通过共挤出得到PLTM-LPs@Gen。此外，还研究了 PLTM-LPs@Gen 的生物学和理化特性。最后，利用细胞模型和荷瘤裸鼠模型评价PLTM-LPs@Gen对肺癌的靶向能力、治疗效果和安全性。LPs@Gen的最佳制备比例为Gen：大豆卵磷脂：胆固醇：DSPE-PEG2000（3:30:5:10，质量比），而LPs@Gen与PLTM的理想融合比例为1:1。 PLTM-LPs@Gen的粒径为108.33±1.06 nm，包封率和载药量分别为94.29%和3.09%。 Gen 是从 PLTM-LPs@Gen 中持续缓慢地释放的。此外，PLTM-LPs@Gen 在一周内表现出良好的稳定性。体外细胞摄取和体内分布实验结果表明，载体材料PLTM-LPs具有免疫逃逸能力和肿瘤靶向能力。因此，它在体外和体内肿瘤模型中表现出比游离药物和传统LP更好的治疗效果。此外，安全性实验表明PLTM-LPs@Gen具有良好的生物相容性。仿生纳米医学为临床上肺癌的精准治疗提供了新策略。© 2024 高等人。

Genistein (Gen), a natural polyphenolic compound, has emerged as a promising candidate for lung cancer treatment. However, the potential clinical application of Gen is limited due to its poor solubility, low bioavailability, and toxic side effects. To address these challenges, a biomimetic delivery platform with cell membranes derived from natural cells as carrier material was constructed. This innovative approach aims to facilitate targeted drug delivery and solve the problem of biocompatibility of synthetic materials.First, the liposomes (LPs) loaded with Gen (LPs@Gen) was prepared using the ethanol injection method. Subsequently, PLTM-LPs@Gen was obtained through co-extrusion after mixing platelet membrane (PLTM) and LPs@Gen. Additionally, the biological and physicochemical properties of PLTM-LPs@Gen were investigated. Finally, the targeting ability, therapeutic efficacy, and safety of PLTM-LPs@Gen for lung cancer were evaluated using both a cell model and a tumor-bearing nude mouse model.The optimal preparation ratio for LPs@Gen was Gen: soybean lecithin: cholesterol: DSPE-PEG2000 (3:30:5:10, mass ratio), while the ideal fusion ratio of LPs@Gen and PLTM was 1:1. The particle size of PLTM-LPs@Gen was 108.33 ± 1.06 nm, and the encapsulation efficiency and drug loading were 94.29% and 3.09% respectively. Gen was released continuously and slowly from PLTM-LPs@Gen. Moreover, PLTM-LPs@Gen exhibited good stability within one week. The results of in vitro cellular uptake and in vivo distribution experiments indicated that the carrier material, PLTM-LPs, has the immune escape ability and tumor targeting ability. Consequently, it showed better therapeutic effects than free drugs and traditional LPs in vitro and in vivo tumor models. In addition, safety experiments demonstrated that PLTM-LPs@Gen possesses good biocompatibility.Biomimetic nanomedicine provides a new strategy for the precision treatment of lung cancer in clinical practice.© 2024 Gao et al.